Blueprint Medicines Corp. inked a potential $1 billion deal with Roche AG units F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. covering the discovery, development and commercialization of up to five small-molecule drugs targeting kinases deemed important in cancer immunotherapy – both as monotherapy and, potentially, in combination with drugs in Roche’s portfolio.